Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir vs Adefovir in Nucleoside-Naive Chronic Hepatitis B
NCT00096785Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at 12 weeks. Started Dec 2004; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00096785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096785.